(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 October 2025 (16.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/214350 A1

(51) International Patent Classification:
C07D 513/22 (2006.01) *A61K 31/4985* (2006.01)
C07D 471/22 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/CN2025/087799

(22) International Filing Date:
08 April 2025 (08.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2024/086658
08 April 2024 (08.04.2024) CN
PCT/CN2024/114877
27 August 2024 (27.08.2024) CN
PCT/CN2024/133341
20 November 2024 (20.11.2024) CN
PCT/CN2024/137535
06 December 2024 (06.12.2024) CN
PCT/CN2024/141123
20 December 2024 (20.12.2024) CN

(71) Applicant: **SUNRISE ONCOLOGY (HONG KONG) LIMITED** [CN/CN]; Suite 603, 6/f Laws Commercial Plaza, 788 Cheung Sha Wan Road, HK (CN).

(72) Inventors: **TONG, Xiaotian**; Room 1001, Building 1, No. 58, Tanzhu Road, Minhang District, Shanghai 201100 (CN). **ZHOU, Wenbo**; Room 1001, Building 1, No. 58, Tanzhu Road, Minhang District, Shanghai 201100 (CN). **CHEN, Huang**; Room 1001, Building 1, No. 58, Tanzhu Road, Minhang District, Shanghai 201100 (CN). **LU, Jian**; Room 1001, Building 1, No. 58, Tanzhu Road, Minhang District, Shanghai 201100 (CN). **PENG, Shihong**; Room 1001, Building 1, No. 58, Tanzhu Road, Minhang District, Shanghai 201100 (CN). **LIU, Mingyao**; Room 1001, Building 1, No. 58, Tanzhu Road, Minhang District, Shanghai 201100 (CN).


(74) Agent: **XU & PARTNERS, LLC.**; Room No.106, Building No.1, Universal High-Tech Plaza., 958 Zhen Bei Road, Putuo District, Shanghai 200333 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: MACROCYCLIC COMPOUNDS AS RAS INHIBITORS FOR THE TREATMENT OF CANCER



(I)

(57) Abstract: Related to macrocyclic compounds and therapeutic uses thereof. Disclosed a compound of formula (I), or a pharmaceutically acceptable salt thereof, a solvate thereof or a solvate of the pharmaceutically acceptable salt, and their use for the preparation of a medicament of treatment of cancer. Provided herein are useful compounds for the inhibition of RAS mutant and the compound shows good inhibitory activity against RAS.

WO 2025/214350 A1